

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Acquisition
Novartis Meets All Tender Offer Conditions to Acquire MorphoSys for EUR 68 per Share
Details : Novartis will begin to progress the integration of MorphoSys, including full access to CPI-0610 (pelabresib), a novel BET inhibitor in combination with ruxolitinib for patients with myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 16, 2024
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Acquisition

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Details : Pelabresib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hematologic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Pelabresib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $2,897.9 million
Deal Type : Acquisition
Novartis Acquires MorphoSys AG To Strengthen Oncology Pipeline
Details : Novartis aims to enhance its oncology pipeline with CPI-0610 (pelabresib), a novel treatment for myelofibrosis with a favorable safety profile when combined with ruxolitinib.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $2,897.9 million
February 05, 2024
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $2,897.9 million
Deal Type : Acquisition

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CPI-0610 (pelabresib monohydrate) is an investigational BET inhibitor. It is being developed in combination with the JAK inhibitor ruxolitinib for the treatment of myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 20, 2023
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain proteins to decrease the expression of abnormally expressed genes in cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Details : Pelabresib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2022
Lead Product(s) : Pelabresib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
Details : Pelabresib durably reduced inflammatory cytokines such as tumor necrosis factor alpha (TNF alpha) and interleukin 18 (IL18) as early as 2 weeks and maintained through 24 weeks of treatment, based on an analysis of patient samples.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2021
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : MorphoSys
Deal Size : $1,700.0 million
Deal Type : Acquisition
Morphosys to Buy Constellation in $1.7B Deal, Aided by Unusual Funding
Details : Constellation's lead product candidates, pelabresib (CPI-0610), a BET inhibitor, and CPI-0209, a 2nd-gen EZH2 inhibitor, are in mid- to late-stage clinical trials and have broad therapeutic potential to offer benefits to patients with various hematologic...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $1,700.0 million
June 02, 2021
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : MorphoSys
Deal Size : $1,700.0 million
Deal Type : Acquisition

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Event includes a review of the clinical and translational data from MANIFEST presented during ASH, including 24-week data from 50-60 first line and 90-100 second line myelofibrosis patients. MANIFEST is an open-label Phase 2 trial of CPI-0610 in patients...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Pelabresib,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pelabresib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Details : Pelabresib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : Pelabresib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable


 
															 Reset All
Reset All